A GLP-1/GDF15 dual agonist / Cell Metab., Jan. 26, 2023 (Vol. 35, Issue 2)

Yuanyuan Zhang, Alexei Kharitonenkov, and colleagues have developed QL1005, a GLP-1/GDF15 hybrid molecule with balanced pathway activation, which can effectively lower body weight via reductions in caloric intake in multiple animal models. In a non-human primate model of obesity, QL1005’s safety and tolerability are similar to that of incretin-based therapies.
Check out the paper at www.cell.com/ce....
Y. Zhang, X. Zhao, X. Dong, Y. Zhang, H. Zou, Y. Jin, W. Guo, P. Zhai, X. Chen, and A. Kharitonenkov (2023). Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates. Cell Metab. 35.
And read more great research at www.cell.com/ce....

[@ourfamilychannel9309]

Would love to see you do a Q&A or even a livestream. Brilliant insights xxx